Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus

被引:18
作者
Handelsman, Yehuda [1 ]
Jellinger, Paul S. [2 ,3 ]
机构
[1] Metab Inst Amer, Tarzana, CA 91356 USA
[2] Univ Miami, Dept Endocrinol, Sch Med, Miami, FL USA
[3] Ctr Diabet & Endocrine Care, Hollywood, FL USA
关键词
IMPROVES GLYCEMIC CONTROL; DOSE COMBINATION THERAPY; CLINICAL INERTIA; COLESEVELAM HYDROCHLORIDE; LDL CHOLESTEROL; PRIMARY-CARE; FOLLOW-UP; MULTIFACTORIAL INTERVENTION; TREATMENT FAILURE; INSULIN GLARGINE;
D O I
10.1111/j.1751-7176.2011.00490.x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Type 2 diabetes mellitus (T2DM) is characterized by progressively worsening hyperglycemia that leads to microvascular and macrovascular complications. Optimal management of T2DM aims to simultaneously control hyperglycemia, hypertension, and dyslipidemia to reduce the overall risk. However, a large proportion of patients in clinical practice do not reach treatment targets. Some of the obstacles to achieving treatment targets include high medication costs, costs associated with health insurance, poor patient adherence to medication, patient fear of potential adverse effects, improper patient education, and failure by health care providers to appropriately initiate or intensify therapy (clinical inertia). Possible causes of clinical inertia include the influence exerted on physicians by reluctant patients and the influence of media-driven attention and the negative spin of clinical trial results on physicians' prescribing behavior and on patients' attitudes towards treatment. This negative publicity can be disproportionate to the overall body of scientific evidence and may, therefore, prove to be unfounded in the long-term. There is clear evidence of the benefits of the effective management of T2DM to achieve goals. Overcoming the obstacles to achieving treatment targets may include use of strategies such as early intensive treatment and combination therapy with drugs with complementary mechanisms of action. J Clin Hypertens (Greenwich). 2011; 13: 613-620. (C)2011 Wiley Periodicals, Inc.
引用
收藏
页码:613 / 620
页数:8
相关论文
共 75 条
[61]   Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial [J].
Riddle, Matthew C. ;
Ambrosius, Walter T. ;
Brillon, David J. ;
Buse, John B. ;
Byington, Robert P. ;
Cohen, Robert M. ;
Goff, David C., Jr. ;
Malozowski, Saul ;
Margolis, Karen L. ;
Probstfield, Jeffrey L. ;
Schnall, Adrian ;
Seaquist, Elizabeth R. .
DIABETES CARE, 2010, 33 (05) :983-990
[62]  
Rivers Shannon M, 2007, Endocr Pract, V13, P11
[63]  
Rodbard H.W., 2007, ENDOCR PRACT, V13, P1, DOI [10.4158/EP.13.S1.1, DOI 10.4158/EP.13.S1.1]
[64]   STATEMENT BY AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS PANEL ON TYPE 2 DIABETES MELLITUS: AN ALGORITHM FOR GLYCEMIC CONTROL [J].
Rodbard, Helena W. ;
Jellinger, Paul S. ;
Davidson, Jaime A. ;
Einhorn, Daniel ;
Garber, Alan J. ;
Grunberger, George ;
Handelsman, Yehuda ;
Horton, Edward S. ;
Lebovitz, Harold ;
Levy, Philip ;
Moghissi, Etie S. ;
Schwartz, Stanley S. ;
Gavin, James R., III .
ENDOCRINE PRACTICE, 2009, 15 (06) :540-559
[65]   Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes [J].
Rosenstock, J. ;
Rood, J. ;
Cobitz, A. ;
Biswas, N. ;
Chou, H. ;
Garber, A. .
DIABETES OBESITY & METABOLISM, 2006, 8 (06) :650-660
[66]  
Rubin Richard R, 2005, Am J Med, V118 Suppl 5A, p27S
[67]   Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes [J].
Saydah, SH ;
Fradkin, J ;
Cowie, CC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (03) :335-342
[68]   Clinical inertia in response to inadequate glycemic control - Do specialists differ from primary care physicians? [J].
Shah, BR ;
Hux, JE ;
Laupacis, A ;
Zinman, B ;
van Walraven, C .
DIABETES CARE, 2005, 28 (03) :600-606
[69]   Educating patients with type 2 diabetes on new class of drug, dipeptidyl peptidase 4 inhibitors [J].
Siminerio, Linda .
DIABETES EDUCATOR, 2007, 33 :111S-113S
[70]   Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [J].
Skyler, Jay S. ;
Bergenstal, Richard ;
Bonow, Robert O. ;
Buse, John ;
Deedwania, Prakash ;
Gale, Edwin A. M. ;
Howard, Barbara V. ;
Kirkman, M. Sue ;
Kosiborod, Mikhail ;
Reaven, Peter ;
Sherwin, Robert S. .
DIABETES CARE, 2009, 32 (01) :187-192